Search

Your search keyword '"Naciu, Anda Mihaela"' showing total 157 results
Start Over Author "Naciu, Anda Mihaela"
157 results on '"Naciu, Anda Mihaela"'

12. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.

Author

Birtolo, Maria Francesca, Pedersini, Rebecca, Palermo, Andrea, Vena, Walter, Morenghi, Emanuela, Cristofolini, Giacomo, Presciuttini, Barbara, Tabacco, Gaia, Naciu, Anda Mihaela, Pigni, Stella, Laganà, Marta, Mazzoleni, Federica, Cosentini, Deborah, Ciafardini, Antea, Pagani, Mauro, Farina, Davide, Balzarini, Luca, Zambelli, Alberto, Torrisi, Rosalba, and Cianferotti, Luisella

Subjects
VERTEBRAL fractures, BONE health, BONE density, HIP fractures, BONE fractures
Abstract

Background Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown. Methods This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months. Results After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg/6 months, 86 bisphosphonates). After 47.0 ± 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P =.028), family history of hip fractures or VFs (OR 3.21, P =.040], chemotherapy-induced menopause (OR 6.48, P <.001), preexisting VFs (OR 25.36, P <.001), baseline T -score less than or equal to −2.5 standard deviation (SD) at any skeletal site (OR 4.14, P =.036), and changes at lumbar and total hip BMD (OR 0.94, P =.038 and OR 0.88, P <.001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14/69, 20.8% vs 2/237, 0.8%; P <.001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P <.001), family history of fractures (OR 0.03; P <.001), chemotherapy-induced menopause (OR 0.04; P <.001), and preexisting VFs (OR 0.01; P <.001). Conclusions Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?

Author

Anastasilakis, Athanasios D, Yavropoulou, Maria P, Palermo, Andrea, Makras, Polyzois, Paccou, Julien, Tabacco, Gaia, Naciu, Anda Mihaela, and Tsourdi, Elena

Abstract

Osteoanabolic agents are used as a first line treatment in patients at high fracture risk. The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bone strength by activating PTH receptors on osteoblasts. Romosozumab (ROMO), a humanized monoclonal antibody against sclerostin, dramatically but transiently stimulates bone formation and persistently reduces bone resorption. Osteoanabolic agents increase BMD and bone strength while being more effective than antiresorptives in reducing fracture risk in postmenopausal women. However, direct comparisons of the antifracture benefits of osteoanabolic therapies are limited. In a direct comparison of TPTD and ABL, the latter resulted in greater BMD increases at the hip. While no differences in vertebral or non-vertebral fracture risk were observed between the two drugs, ABL led to a greater reduction of major osteoporotic fractures. Adverse event profiles were similar between the two agents except for hypercalcemia, which occurred more often with TPTD. No direct comparisons of fracture risk reduction between ROMO and the PTH1R agonists exist. Individual studies have shown greater increases in BMD and bone strength with ROMO compared with TPTD in treatment-naive women and in women previously treated with bisphosphonates. Some safety aspects, such as a history of tumor precluding the use of PTH1R agonists, and a history of major cardiovascular events precluding the use of ROMO, should also be considered when choosing between these agents. Finally, convenience of administration, reimbursement by national health systems and length of clinical experience may influence patient choice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Bone and Diabetes

Author

Palermo, Andrea, Naciu, Anda Mihaela, Tabacco, Gaia, D’Onofrio, Luca, Napoli, Nicola, Lenzi, Andrea, editor, and Migliaccio, Silvia, editor

Published
2018
Full Text
View/download PDF

19. Thyroid cancer diagnosis by Raman spectroscopy

Author

Sbroscia, Marco, Di Gioacchino, Michael, Ascenzi, Paolo, Crucitti, Pierfilippo, di Masi, Alessandra, Giovannoni, Isabella, Longo, Filippo, Mariotti, Davide, Naciu, Anda Mihaela, Palermo, Andrea, Taffon, Chiara, Verri, Martina, Sodo, Armida, Crescenzi, Anna, and Ricci, Maria Antonietta

Published
2020
Full Text
View/download PDF

22. PSAT379 Performance of a Raman Fingerprint in Thyroid Nodules with Indeterminate Cytology: A Prospective Blinded Monocentric Study

Author

Palermo, Andrea, primary, Sodo, Armida, additional, Naciu, Anda Mihaela, additional, Gioacchino, Michael D, additional, Paolucci, Alessio, additional, Masi, Alessandra D, additional, Maggi, Daria, additional, Crucitti, Pierfilippo, additional, Longo, Filippo, additional, Perrella, Eleonora, additional, Taffon, Chiara, additional, Verri, Martina, additional, Ricci, Maria Antonietta, additional, and Crescenzi, Anna, additional

Published
2022
Full Text
View/download PDF

23. Clinical Use of Raman Spectroscopy Improves Diagnostic Accuracy for Indeterminate Thyroid Nodules

Author

Palermo, Andrea, primary, Sodo, Armida, additional, Naciu, Anda Mihaela, additional, Di Gioacchino, Michael, additional, Paolucci, Alessio, additional, di Masi, Alessandra, additional, Maggi, Daria, additional, Crucitti, Pierfilippo, additional, Longo, Filippo, additional, Perrella, Eleonora, additional, Taffon, Chiara, additional, Verri, Martina, additional, Ricci, Maria Antonietta, additional, and Crescenzi, Anna, additional

Published
2022
Full Text
View/download PDF

24. Unraveling the Effects of Carotenoids Accumulation in Human Papillary Thyroid Carcinoma

Author

di Masi, Alessandra, primary, Sessa, Rosario Luigi, additional, Cerrato, Ylenia, additional, Pastore, Gianni, additional, Guantario, Barbara, additional, Ambra, Roberto, additional, Di Gioacchino, Michael, additional, Sodo, Armida, additional, Verri, Martina, additional, Crucitti, Pierfilippo, additional, Longo, Filippo, additional, Naciu, Anda Mihaela, additional, Palermo, Andrea, additional, Taffon, Chiara, additional, Acconcia, Filippo, additional, Bianchi, Fabrizio, additional, Ascenzi, Paolo, additional, Ricci, Maria Antonietta, additional, and Crescenzi, Anna, additional

Published
2022
Full Text
View/download PDF

25. Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double‐Blind, Crossover Clinical Trial

Author

Naciu, Anda Mihaela, primary, Tabacco, Gaia, additional, Bilezikian, John P, additional, Santonati, Assunta, additional, Bosco, Daniela, additional, Incognito, Giosuè Giordano, additional, Gaspa, Gianluigi, additional, Manfrini, Silvia, additional, Falchetti, Alberto, additional, Trimboli, Pierpaolo, additional, Mazziotti, Gherardo, additional, Napoli, Nicola, additional, Sanson, Gianfranco, additional, Cesareo, Roberto, additional, Vescini, Fabio, additional, and Palermo, Andrea, additional

Published
2022
Full Text
View/download PDF

30. Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism

Author

Naciu, Anda Mihaela, primary, Tabacco, Gaia, additional, Falcone, Stefania, additional, Incognito, Giosuè Giordano, additional, Chiodini, Iacopo, additional, Maggi, Daria, additional, Pedone, Claudio, additional, Lelli, Diana, additional, Bilezikian, John P., additional, Napoli, Nicola, additional, Manfrini, Silvia, additional, Cesareo, Roberto, additional, and Palermo, Andrea, additional

Published
2021
Full Text
View/download PDF

31. Long‐term efficacy and safety of percutaneous ethanol injection (PEI) in cystic thyroid nodules: A systematic review and meta‐analysis

Author

Cesareo, Roberto, primary, Tabacco, Gaia, additional, Naciu, Anda Mihaela, additional, Crescenzi, Anna, additional, Bernardi, Stella, additional, Romanelli, Francesco, additional, Deandrea, Maurilio, additional, Trimboli, Pierpaolo, additional, Palermo, Andrea, additional, and Castellana, Marco, additional

Published
2021
Full Text
View/download PDF

32. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature

Author

Briganti, Silvia Irina, Naciu, Anda Mihaela, Tabacco, Gaia, Cesareo, Roberto, Napoli, Nicola, Trimboli, Pierpaolo, Castellana, Marco, Manfrini, Silvia, and Palermo, Andrea

Subjects
Article Subject
Abstract

Despite the large number of patients worldwide being on proton pump inhibitors (PPIs) for acid-related gastrointestinal disorders, uncertainty remains over their long-term safety. Particularly, the potential side effects of these drugs on bone health have been evaluated in the last years. The purpose of our narrative review is to gather and discuss results of clinical studies focusing on the interactions between PPIs and fracture risk. Data generated mainly from nested case-control studies and meta-analysis suggest that long-term/high-dose PPIs users are characterized by an increased risk of fragility fractures, mainly hip fractures. However, in these studies, the PPIs-induced bone impairment is often not adjusted for different confounding variables that could potentially affect bone health, and exposure to PPIs was reported using medical prescriptions without adherence evaluation. The mechanisms of the PPI-related bone damage are still unclear, but impaired micronutrients absorption, hypergastrinemia, and increased secretion of histamine may play a role. Clinicians should pay attention when prescribing PPIs to subjects with a preexistent high risk of fractures and consider antiosteoporotic drugs to manage this additive effect on the bone. However, further studies are needed to clarify PPIs action on the bone.

Published
2021
Full Text
View/download PDF

37. Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas

Author

Sodo, Armida, primary, Verri, Martina, additional, Palermo, Andrea, additional, Naciu, Anda Mihaela, additional, Sponziello, Marialuisa, additional, Durante, Cosimo, additional, Di Gioacchino, Michael, additional, Paolucci, Alessio, additional, di Masi, Alessandra, additional, Longo, Filippo, additional, Crucitti, Pierfilippo, additional, Taffon, Chiara, additional, Ricci, Maria Antonietta, additional, and Crescenzi, Anna, additional

Published
2020
Full Text
View/download PDF

38. Trabecular bone score in subjects with normocalcemic hyperparathyroidism

Author

Naciu, Anda Mihaela, primary, Tabacco, Gaia, additional, Falcone, Stefania, additional, Santonati, Assunta, additional, Briganti, Silvia Irina, additional, Lelli, Diana, additional, Pedone, Claudio, additional, Fabbri, Andrea, additional, Chiodini, Iacopo, additional, Bilezikian, John Paul, additional, Napoli, Nicola, additional, Manfrini, Silvia, additional, Cesareo, Roberto, additional, and Palermo, Andrea, additional

Published
2020
Full Text
View/download PDF

39. Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism

Author

Palermo, Andrea, primary, Naciu, Anda Mihaela, additional, Tabacco, Gaia, additional, Falcone, Stefania, additional, Santonati, Assunta, additional, Maggi, Daria, additional, D’Onofrio, Luca, additional, Briganti, Silvia Irina, additional, Castellitto, Domenico, additional, Casini, Alessandro, additional, Pedone, Claudio, additional, Lelli, Diana, additional, Fabbri, Andrea, additional, Bilezikian, John P, additional, Napoli, Nicola, additional, Pozzilli, Paolo, additional, Manfrini, Silvia, additional, and Cesareo, Roberto, additional

Published
2020
Full Text
View/download PDF

40. Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer

Author

Palermo, Andrea, primary, Napolitano, Andrea, additional, Maggi, Daria, additional, Naciu, Anda Mihaela, additional, Tabacco, Gaia, additional, Manfrini, Silvia, additional, Crescenzi, Anna, additional, Taffon, Chiara, additional, Pantano, Francesco, additional, Vincenzi, Bruno, additional, Tonini, Guiseppe, additional, and Santini, Daniele, additional

Published
2020
Full Text
View/download PDF

41. Long‐term efficacy and safety of percutaneous ethanol injection (PEI) in cystic thyroid nodules: A systematic review and meta‐analysis.

Author

Cesareo, Roberto, Tabacco, Gaia, Naciu, Anda Mihaela, Crescenzi, Anna, Bernardi, Stella, Romanelli, Francesco, Deandrea, Maurilio, Trimboli, Pierpaolo, Palermo, Andrea, and Castellana, Marco

Subjects
THYROID nodules, TREATMENT effectiveness, SCIENCE databases, WEB databases, ETHANOL, NEEDLE biopsy
Abstract

Background: Percutaneous ethanol injection (PEI) is used for the treatment of benign cystic thyroid nodules. This systematic review and meta‐analysis aimed to obtain strong evidence of its long‐term efficacy and safety. Methods: PubMed, CENTRAL, Scopus and Web of Science databases were searched until November 2020 for studies reporting data on volume reduction rate (VRR), compressive symptoms and cosmetic concerns. Associated complications were assessed. A random‐effects model was designed to pool the data. Results: Out of 385 papers, nine studies evaluating 1667 nodules were finally included. Overall, VRR at 6, 12, 24, 36, 60 and 120 months was 77%, 81%, 72%, 68%, 74% and 69%, respectively. Significant reductions in the compressive symptoms and cosmetic concerns were observed. No permanent complications were observed. Conclusions: The present meta‐analysis showed that PEI could significantly reduce the volume of benign cystic thyroid nodules. This reduction was already effective at 6 months post‐treatment, and the effect was stable over time. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Cardiovascular autonomic neuropathy as a cause of fatigue in chronic hypoparathyroidism

Author

Tabacco, Gaia, primary, Naciu, Anda Mihaela, additional, Cesareo, Roberto, additional, Maggi, Daria, additional, Pedone, Claudio, additional, Lelli, Diana, additional, Santonati, Assunta, additional, Bosco, Daniela, additional, Di Tommaso, Alfonso Maria, additional, Pozzilli, Paolo, additional, Manfrini, Silvia, additional, and Palermo, Andrea, additional

Published
2019
Full Text
View/download PDF

44. Clinical, biochemical and radiological profile of normocalcaemic hyperparathyroidism: a multicentric cross-sectional evaluation

Author

Naciu, Anda Mihaela, primary, Tabacco, Gaia, additional, Falcone, Stefania, additional, Santonati, Assunta, additional, Maggi, Daria, additional, D'Onofrio, Luca, additional, Briganti, Silvia Irina, additional, Castellitto, Domenico, additional, Casini, Alessandro, additional, Pedone, Claudio, additional, Fabbri, Andrea, additional, Napoli, Nicola, additional, Pozzilli, Paolo, additional, Manfrini, Silvia, additional, Cesareo, Roberto, additional, and Palermo, Andrea, additional

Published
2019
Full Text
View/download PDF

45. MON-533 Irisin in Post-Menopausal Women with Primary Hyperparathyroidism: An Interplay between Irisin and Pth

Author

Palermo, Andrea, primary, Sanesi, Lorenzo, additional, Colaianni, Graziana, additional, Tabacco, Gaia, additional, Naciu, Anda Mihaela, additional, Cesareo, Roberto, additional, Pedone, Claudio, additional, Lelli, Diana, additional, Brunetti, Giacomina, additional, Mori, Giorgio, additional, Colucci, Silvia, additional, Manfrini, Silvia, additional, Napoli, Nicola, additional, and Grano, Maria, additional

Published
2019
Full Text
View/download PDF

46. A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism

Author

Palermo, Andrea, primary, Sanesi, Lorenzo, additional, Colaianni, Graziana, additional, Tabacco, Gaia, additional, Naciu, Anda Mihaela, additional, Cesareo, Roberto, additional, Pedone, Claudio, additional, Lelli, Diana, additional, Brunetti, Giacomina, additional, Mori, Giorgio, additional, Colucci, Silvia, additional, Manfrini, Silvia, additional, Napoli, Nicola, additional, and Grano, Maria, additional

Published
2019
Full Text
View/download PDF

47. Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism

Author

Tabacco, Gaia, primary, Naciu, Anda Mihaela, additional, Maggi, Daria, additional, Santonati, Assunta, additional, Pedone, Claudio, additional, Cesareo, Roberto, additional, Bosco, Daniela, additional, Gaspa, Gianluigi, additional, Napoli, Nicola, additional, Pozzilli, Paolo, additional, Manfrini, Silvia, additional, and Palermo, Andrea, additional

Published
2018
Full Text
View/download PDF

48. A Rare Complication following Thyroid Percutaneous Ethanol Injection: Plummer Adenoma

Author

Cesareo, Roberto, Naciu, Anda Mihaela, Pasqualini, Valerio, Pelle, Giuseppe, Manfrini, Silvia, Tabacco, Gaia, Lauria Pantano, Angelo, Casini, Alessandro, Cianni, Roberto, and Palermo, Andrea

Subjects
endocrine system diseases, Article Subject, macromolecular substances
Abstract

Percutaneous ethanol injection (PEI) is a technique used only for benign thyroid nodules, cystic or mixed cystic-solid with a large fluid component. It is a quite low-cost, safe, and outpatient method of treatment. Rare and severe complications have been described after PEI: jugular vein thrombosis and severe ethanol toxic necrosis of the larynx combined with necrotic dermatitis. Moreover, only four thyrotoxicosis cases due to Graves’ disease have been reported. We report a case of 58-year-old female with a voluminous thyroid cystic nodule, occupying almost the entire left thyroid lobe. Our patient had already performed surgical visit and intervention of thyroidectomy had been proposed to her, which she refused. At baseline, our patient has a normal thyroid function with negative autoantibodies. According to the nodular structure, intervention of PEI has been performed with a significant improvement of compressive symptoms and cosmetic disorders. About 30 days after treatment, there was a significant volume reduction, but patient developed an acclaimed symptomatic thyrotoxicosis. After ruling out several causes of hyperthyroidism and according to the thyroid scintigraphy findings, we made the diagnosis of Plummer adenoma. To our knowledge, our patient is the first case of Plummer adenoma following PEI treatment of nontoxic thyroid nodule.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results